Long-term cultivation of plasma cell leukemia cells and autologous lymphoblasts (LCL) in vitro: A comparative study

Abstract

Two long-term cell lines were established in vitro from the peripheral blood of a patient with plasma cell leukemia: one line with plasma cell proliferation, the other with lymphoblastoid cell proliferation (LCL). The 9-month-old plasma cell line showed the typical morphology of plasmoblasts. The cells neither had B- nor T-lymphocyte characterisitics, were EBV negative, and showed aneuploidy with various marker chromosomes, including the 14 q+ marker. The cytogenetic findings indicate a monoclonal proliferation of the plasmacells. No tumor growth in thymusless nude mice could be induced upon intracranial inoculation with these cells. In contrast, the autologous LCL, cultured after addition of exogenous EBV, showed the characteristic markers of lymphoblastoid cells, with the typical morphology of pear- and handmirror-shaped lymphoblasts, growing in clumps. They had C3- and Fc-receptors, surface-Ig, E-rosette-negativity, a diploid karyotype, and EBV dependent macromolecule synthesis. They lymphoblastoid cells produced intracranial tumors in nude mice in 8 out of 8 attempts.

A bioluminescence imaging based in vivo model for preclinical testing of novel cellular immunotherapy strategies to improve the graft-versus-myeloma effect

“…The human MM cell lines that we studied were U266, RPMI-8226/S (both obtained from the American Tissue Culture Collection (ATCC), UM-9 (generated in our institute) 16 , LME-1 17 , XG-1 18 OPM-1 19 , and L-363 20 . All MM cell lines were cultured in RPMI-1640 (Gibco, Breda, The Netherlands) supplemented with 10% fetal calf serum (Integro, Zaandam, The Netherlands), 100 U/mL penicillin (Gibco), 100 µg/mL streptomycin (Gibco), and 10 µM β-mercaptoethanol (Merck, Darmstadt, Germany).…”

Epigenetic silencing of the interferon regulatory factor ICSBP/IRF8 in human multiple myeloma

“…Human MM cell lines U-266-1970 [18], U-266-1984 [19], U-1957 [19], U-1958 [19], U-1996 [19], Karpas 707 [20], HL461 [21], HL407 [22], L 363 [23], JJN-3 [24], EJM [24], LP-1 [25], RPMI 8226 [26], OPM-2 [19]; the human monoblastic cell line U-937 [27]; the T-cell line Jurkat [28]; the Burkitt's lymphoma BJAB [29], the acute lymphoblastic leukemia cell lines KM-3 [28], NALM-16 [30], NALL-1 [31], and the Epstein-Barr viruscarrying lymphoblastoid B-cell lines CESS [32], and Corinna II [33] were maintained in RPMI-1640 (Sigma-Aldrich, St. Louis, MO, USA) medium plus 10% fetal bovine serum and antibiotics in a humidified atmosphere containing 5% CO 2 at 37 C.…”

The hepatocyte growth factor/Met pathway controls proliferation and apoptosis in multiple myeloma

“…XG-1 and UM6 were cultured in the presence of 500 pg/ml IL6 (R&D Systems). MM cell lines UM1 and UM3, 18 L363, 19 NCI H929, 20 and OPM-1 21 were cultured in RPMI 1640 (Life Technologies, Breda, The Netherlands) containing 10% fetal calf serum (Integro). Burkitt parental Namalwa and the Met-transfected cell line Namalwa (Nam Met ) 22 were cultured in RPMI 1640 supplemented with 10% fetal clone I serum, 2 mM L-glutamine, 100 IU/ml penicillin, and 100 IU/ml streptomycin (all Life Technologies).…”